Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.

ABSTRACT:

Importance

It remains unclear why only a small proportion of individuals infected with the Epstein-Barr virus (EBV) develop multiple sclerosis (MS) and what the underlying mechanisms are.

Objective

To assess the serologic response to all EBV peptides before the first symptoms of MS occur, determine whether the disease is associated with a distinct immune response to EBV, and evaluate whether specific EBV epitopes drive this response.

Design, setting, and participants

In this prospective, nested case-control study, individuals were selected among US military personnel with serum samples stored in the US Department of Defense Serum Repository. Individuals with MS had serum collected at a median 1 year before onset (reported to the military in 2000-2011) and were matched

SUBMITTER: Cortese M 

PROVIDER: S-EPMC10949154 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature